Galenica has reinforced its position as the leading player in the Swiss OTC market through the acquisition of Hedoga Group,

Reckitt will work with former Sanofi partner ResApp to develop a consumer app which can diagnose common respiratory issues. The partnership represents RB's latest move into the digital space for its Health business.

Perrigo’s ambitions to become a consumer-focused company are a step closer after the firm announced an immediate sale of a ‘non-core’ asset.

Sensory Cloud’s small study showed FEND nasal solution cut by 99% exhalation of bioaerosol to block COVID-19. Global BioProtect’s hand sanitizer with proprietary antibacterial technology eliminates 45 bacteria, fungi and virus. Trilogy Labs’  solution replenishes moisture in hands irritated by sanitizers.

Pataday Once Daily Relief Extra Strength is the same formulation as Novartis' Rx Pazeo. It will be the first OTC eye drop indicated for allergy itch with 24-hour efficacy, available online in September and through retailers in early 2021.

Appropriations Committee’s report with Agriculture, Rural Development, FDA and Related Agencies FY2021 budget bill also reiterated concern about adding acetaminophen dosing information for children to OTC monograph. But its mentions of FDA initiative to expand ingredients available OTC and homeopathic market oversight were firsts.

Acquiring France's UPSA helped to lift Taisho's sales in the 12 months ended 31 March 2020, as its domestic Japanese business faltered.

Charlotte’s Web is strengthening its DTC lead while growing its brick-and-mortar retail business, accelerating its pet product distribution and working to close its Abacus Health acquisition announced in March. The Boulder, CO-based CBD product manufacturer posted a 1% decline in net sales for the first quarter, but expects a rapid escalation in the second half of the year.

CEO Joseph Papa says firm isn’t valued equal to sum of its parts. "If some of the parts don't seem to make sense or don't seem to be capturing the full value of a business,” Bausch “will look at all the alternatives for looking at things like spin-offs of parts of the business,” he says.

Like other hand sanitizer manufacturers, WillSpeed Technology claims its GermBloc “kills 99.99% of germs.” Plaintiffs in a proposed class action filed in Massachusetts federal court allege the claim “grossly overstates” the product’s efficacy, deceiving consumers and endangering them with false confidence.

Johnson & Johnson failed to convince a Missouri appeals court to overturn a lower court finding that plaintiffs presented clear and convincing evidence the talc in its Johnson’s Baby Powder causes ovarian cancer and that the firm knew and improperly influenced regulators to allow use of the ingredient.

J&J’s appeal of largest verdict yet in complaints challenging safety of talc in its Johnson’s Baby Powder and Shower to Shower Shimmer products failed, but a Missouri court cut its damages by more than half. Missouri appellate panel says the firm should pay $500m compensatory and $1.62bn punitive damages.